

March 6, 1970

Dr. G. F. Blane
Reckitt & Sons
Hull, England

Dear Dr. Blane,

Two years ago I wrote to obtain information on narcotic antagonists, particularly 5050-M. At the recent NRC meetings in Washington, a former associate, R. E. Lister, mentioned that you had worked on a long-acting narcotic but may have discarded it because of its unusual length of action.

A long acting narcotic with cross tolerance to opiates would be a most useful adjunct in the treatment of opiate dependence; as would a long acting and potent narcotic antagonist. I am writing to request any information that may be available regarding potential human trials with either of these compounds. Have trials with 5050-M progressed to assessments in man? Is there, indeed, a very long acting analgesic with cross tolerance to opiates available?

As we wrote before, we are actively involved in human trials of these substances, and would appreciate the opportunity to extend these investigations in any meaningful way.

Thank you for your assistance.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

mf/
cc: A. M. Freedman